Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMFKA4G)

• Drug Name: BLZ-100 Drug Info
• Synonyms: Tozuleristide; UNII-835UH424TU; 835UH424TU; Tozuleristide [INN]; Tozuleristide [USAN]; 1673565-40-6

Indication

Disease Entry	ICD 11	Status	REF
Glioma	2A00.0	Phase 1/2	[1]
Malignant primary brain tumour	2A00.0	Phase 1	[2]

• Cross-matching ID:
  PubChem CID: 121488172
  CAS Number: CAS 1673565-40-6
  TTD Drug ID: DMFKA4G

Molecule-Related Drug Atlas

Drug(s) Targeting Matrix metalloproteinase-9 (MMP-9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[3]
DP-b99	DM97S10	Stroke	8B20	Phase 3	[4]
GS-5745	DMP8MDW	Gastric adenocarcinoma	2B72	Phase 3	[5]
Andecaliximab	DMLDB1X	Gastric adenocarcinoma	2B72	Phase 3	[6]
Neovastat	DMXTYWJ	Non-small-cell lung cancer	2C25.Y	Phase 1	[7]
PMID29130358-Compound-Figure18(14a)	DMHIBTZ	N. A.	N. A.	Patented	[8]
PMID29130358-Compound-Figure17(12)	DMML4PA	N. A.	N. A.	Patented	[8]
PMID29130358-Compound-Figure17(10)	DMVA15O	N. A.	N. A.	Patented	[8]
PMID29130358-Compound-SB-3CT	DMC64XQ	N. A.	N. A.	Patented	[8]
PMID29130358-Compound-Figure17(11)	DMSZA9L	N. A.	N. A.	Patented	[8]

Drug(s) Targeting Chloride channel unspecific (ClC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
TM-601	DMKV5UM	Solid tumour/cancer	2A00-2F9Z	Phase 2	[9]
Lancovutide	DM7MBV6	Chronic obstructive pulmonary disease	CA22	Phase 2	[10]
131I-TM-601	DMTIED1	Glioma	2A00.0	Phase 2	[11]
GR-213487	DMCXLIK	Cystic fibrosis	CA25	Discontinued in Phase 2	[12]
TgAAV-CFTR	DMQSNV8	Cystic fibrosis	CA25	Discontinued in Phase 2	[13]
Endovion	DMJU39N	Solid tumour/cancer	2A00-2F9Z	Terminated	[14]

Drug(s) Targeting Matrix metalloproteinase (MMP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Abametapir	DM2RX0I	Head and body lice	1G00.0	Approved	[15]
S-3304	DMCBQTF	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[16]
ABT-518	DMA2RM3	Solid tumour/cancer	2A00-2F9Z	Discontinued in Phase 1	[17]
D-1927	DM5D8JW	Solid tumour/cancer	2A00-2F9Z	Discontinued in Phase 1	[18]
S-3536	DMZYRI3	Osteoarthritis	FA00-FA05	Discontinued in Phase 1	[19]
BB-2983	DMYK8OG	Inflammatory bowel disease	DD72	Discontinued in Phase 1	[20]
ONO-4817	DMKRVUN	Inflammatory bowel disease	DD72	Discontinued in Phase 1	[21]
DFD-11	DMHXVN1	Head and body lice	1G00.0	Application submitted	[22]
D-9120	DMHNZ1P	Inflammatory bowel disease	DD72	Terminated	[23]
D-5410	DMXHN6U	Rheumatoid arthritis	FA20	Terminated	[24]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Chloride channel unspecific (ClC)	TTCYAXN	NOUNIPROTAC	Inhibitor	[1]
Matrix metalloproteinase (MMP)	TT1GHVO	NOUNIPROTAC	Inhibitor	[1]
Matrix metalloproteinase-9 (MMP-9)	TT6X50U	MMP9_HUMAN	Inhibitor	[1]

References

• [1] Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Synthesis and biological evaluation of curcuminoid pyrazoles as new therapeutic agents in inflammatory bowel disease: effect on matrix metalloprote... Bioorg Med Chem. 2009 Feb 1;17(3):1290-6.
• [4] DP-b99 modulates matrix metalloproteinase activity and neuronal plasticity. PLoS One. 2014 Jun 11;9(6):e99789.
• [5] National Cancer Institute Drug Dictionary (drug id 747683).
• [6] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [7] Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials. Semin Oncol. 2001 Dec;28(6):620-5.
• [8] Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46.
• [9] NMR sequential assignments and solution structure of chlorotoxin, a small scorpion toxin that blocks chloride channels. Biochemistry. 1995 Jan 10;34(1):13-21.
• [10] Airway-rehydrating agents for the treatment of cystic fibrosis: past, present, and future. Ann Pharmacother. 2011 Jan;45(1):49-59.
• [11] Imaging glioma extent with 131I-TM-601. J Nucl Med. 2005 Apr;46(4):580-6.
• [12] EP patent application no. 1336602, Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases.
• [13] Novel molecular approaches to cystic fibrosis gene therapy. Biochem J. 2005 April 1; 387(Pt 1): 1-15.
• [14] Inhibition of the endogenous volume-regulated anion channel (VRAC) in HEK293 cells by acidic di-aryl-ureas. J Membr Biol. 2003 Nov 15;196(2):83-94.
• [15] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [16] Safety, tolerability and pharmacokinetics of oral S-3304, a novel matrix metalloproteinase inhibitor, in single and multiple dose escalation studies in healthy volunteers. Int J Clin Pharmacol Ther. 2005 Jun;43(6):282-93.
• [17] Quantitative analysis of the novel anticancer drug ABT-518, a matrix metalloproteinase inhibitor, plus the screening of six metabolites in human plasma using high-performance liquid chromatography coupled with electrospray tandem mass spectrometry. J Mass Spectrom. 2004 Mar;39(3):277-88.
• [18] Correlation of antiangiogenic and antitumor efficacy of N-biphenyl sulfonyl-phenylalanine hydroxiamic acid (BPHA), an orally-active, selective matrix metalloproteinase inhibitor. Cancer Res. 1999 Mar15;59(6):1231-5.
• [19] CIINE Reflects Collagenase-Specific CII Breakdown in Cartilage Explant and Whole Body of Canine. Biomark Insights. 2013; 8: 77-83.
• [20] Matrix metalloproteinase inhibition reduces intimal hyperplasia in a porcine arteriovenous-graft model. J Vasc Surg. 2004 Feb;39(2):432-9.
• [21] ONO-4817, an orally active matrix metalloproteinase inhibitor, prevents lipopolysaccharide-induced proteoglycan release from the joint cartilage in guinea pigs. Inflamm Res. 2000 Apr;49(4):144-6.
• [22] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [23] WO patent application no. 2006,1139,93, Matrix metalloproteinase inhibitors of tgfss -induced subcapsular cataract formation.
• [24] US patent application no. US20080187572 A1.